Who we are
National BioService (NBS) is a fully compliant human biospecimens CRO offering professional services in ethical sourcing, processing and characterization of human and primate biospecimens.
Medical Partners Network
NBS operates a network of over 125 formally contracted and managed clinical Centers in 30 cities across Russia, supported by six NBS own laboratories
Logistics & Compliance
NBS provides its services to customers world-wide in strict compliance with local and international medical, customs and data protection rules and regulations while demonstrating full traceability of biospecimens
Molecular genotyping
Both PCR-based and cost effective NGS-based protocols are implemented in own molecular genetic laboratory
ONLINE BIOREPOSITORY
Our partners
NBS RESEARCH PROJECTS
Lucard
LUCARD (Lung Cancer Residual Disease Study) is the study of minimal residual disease (MRD) in non-small cell lung cancer (NSCLC). Its objective is to determine the relationship between the circulating tumor DNA (ctDNA) profile after surgery and the risk of recurrence. Analysis of ctDNA before and after surgery, as well as testing of tumor material for the presence of somatic mutations is carrying out by NGS technology. Four leading medical centers in Russia are currently involved in the study.
Oncobrca
The oncaBRCA database contains information on the frequencies of variants of the BRCA1 / 2 genes analyzed within the framework of the Hereditary Syndromes Project Study in Russian. More than 2,000 clinical cases from 35 regions of Russia were analyzed using NGS. The goal of the project is to expand knowledge about the genetic basis of breast, ovarian, and other cancers by combining information on BRCA1 / 2 variants and relevant clinical data as well as to help in the interpretation of mutations variants distributed in Russian populations.
AD biomarker
Alzheimer disease (AD) biomarkers are being studied in the cerebrospinal fluid (CSF) for their ability to indicate early stages of Alzheimer's disease by new multiplexed assay panel. The study aims to include beta-amyloid and tau protein levels in cerebrospinal fluid (CSF) and tears in routing neurological patients screening for early detection of AD.